Banook Central Imaging (Banook CI) has been selected by Servier to assess the potential anti-tumor activity of a novel monoclonal antibody based on the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) and Immune-Related Response criteria (IrRC) in a multicenter Phase I study in patients with breast cancer. The study will also incorporate the use of Tumor Growth Rates (TGR), an assessment that provides the growth rate before and after treatment.   Banook CI will use their comprehensive i...